Fake Drug, Fake Illness_People Believe it
Direct to consumer drug advertisements are so successful, they can convince people they're sick and need the advertised drug–
Direct to consumer drug advertisements are so successful, they can convince people they're sick and need the advertised drug–
Direct to consumer drug advertisements are so successful, they can convince people they're sick and need the advertised drug–
Despite Lilly's efforts to suppress the documents, they are available on internet websites.
Judge Jack Weinstein rejected Lilly's effort to seek a court injunction against internet posting
of the documents.
A federal Judge of the Eastern District (Brooklyn) issued a ruling upholding a seal on documents that contain evidence linking Zyprexa, Eli Lilly's antipsychotic drug to diabetes
News headlines in the Boston area report about the death of four year old
Rebecca Riley, the latest child casualty of prescribed psychotropic drugs.
Pharmaceutical companies, much like the tobacco industry, have made fortunes by engaging in lies, deception, and illegal practices that are making people sick and causing premature deaths.
These illegal practices are the secret behind this toxic drug–Zyprexa– becoming a blockbuster seller.
Today's news reports about an increase suicide rate in 2004 offer an opportunity to witness how the media unwittingly disseminates pharmaceutical industry generated propaganda.
Today’s news reports about an increase suicide rate in 2004 offer an opportunity to witness how the media unwittingly disseminates pharmaceutical industry generated propaganda.
BBC-Panorama–third in a series: The Secrets of Seroxat. "In the interests of patients and professional integrity" is to show those who have sold their reputations "intolerance and exposure."
Eli Lilly's latest Zyprexa settlement will not affect civil or criminal investigations pending over Zyprexa from state attorneys general and federal prosecutors, which are continuing.
Only if one assumes that the FDA sees the drug industry as its client can some sense be made of December 13th meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee in Silver Springs, Maryland.